iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) was the target of some unusual options trading activity on Monday. Traders acquired 13,855 call options on the company. This represents an increase of approximately 298% compared to the average volume of 3,480 call options.

Separately, Vetr upgraded shares of iShares Nasdaq Biotechnology Index Fund from a “hold” rating to a “buy” rating and set a $303.00 price objective on the stock in a research report on Wednesday, May 17th.

Institutional investors have recently added to or reduced their stakes in the company. Bollard Group LLC increased its position in iShares Nasdaq Biotechnology Index Fund by 0.3% in the second quarter. Bollard Group LLC now owns 392 shares of the financial services provider’s stock valued at $121,000 after buying an additional 1 shares during the period. Geneva Advisors LLC increased its position in iShares Nasdaq Biotechnology Index Fund by 1.1% in the first quarter. Geneva Advisors LLC now owns 818 shares of the financial services provider’s stock valued at $240,000 after buying an additional 9 shares during the period. Brown Advisory Securities LLC increased its position in iShares Nasdaq Biotechnology Index Fund by 1.2% in the first quarter. Brown Advisory Securities LLC now owns 850 shares of the financial services provider’s stock valued at $250,000 after buying an additional 10 shares during the period. Pinnacle Wealth Management Advisory Group LLC increased its position in iShares Nasdaq Biotechnology Index Fund by 1.1% in the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 890 shares of the financial services provider’s stock valued at $276,000 after buying an additional 10 shares during the period. Finally, Brighton Jones LLC increased its position in iShares Nasdaq Biotechnology Index Fund by 1.5% in the second quarter. Brighton Jones LLC now owns 814 shares of the financial services provider’s stock valued at $252,000 after buying an additional 12 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

iShares Nasdaq Biotechnology Index Fund (IBB) opened at 309.16 on Thursday. iShares Nasdaq Biotechnology Index Fund has a 12-month low of $246.71 and a 12-month high of $329.90. The stock has a 50 day moving average of $314.53 and a 200-day moving average of $299.94.

WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/23/ishares-nasdaq-biotechnology-index-fund-sees-unusually-high-options-volume-ibb.html.

iShares Nasdaq Biotechnology Index Fund Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.